Dr. Abbey Spoke About the VERONA Diabetic Macular Edema Clinical Trial at The Retina Society’s Annual Meeting
On behalf of the VERONA study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered a presentation titled “VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) versus Aflibercept
read more Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting
On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase
read more Dr. Abbey Shares 36-Month Results of Pegcetacoplan Treatment for Geographic Atrophy in AMD
On behalf of the investigators for the OAKS, DERBY, and GALE clinical trials, Texas Retina’s Director of Clinical Research for Dallas, Ashkan Abbey, MD, co-authored an article titled, “Pegcetacoplan Treatment for Geographic
read more
Dr. Laura Discussed Dry AMD Treatment at 2025 Vit-Buckle Society Annual Meeting
Texas Retina’s Diana M. Laura, MD, participated in a debate at the 13th Annual Vit-Buckle Society Meetingheld recently in Austin, Texas, where she discussed the role of complement inhibitors for the treatment
read more
Dr. Abbey Serves as Guest Editor for Latest Issue of Retina Today
Texas Retina’s Ashkan M. Abbey, MD, served as guest medical editor for the January/February 2025 issue of Retina Today along with Christina Y. Weng, MD, from Baylor College of Medicine. Retina Today
read more